The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...
Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...
The retrospective analysis found Black patients were more likely to develop severe graft versus host disease (GVHD) and have a higher risk of nonrelapse mortality than White patients after ...
GVHD is a common and often fatal complication that can follow a bone marrow transplant, which occurs when the donated cells mount an immune response against the transplant recipient’s tissues ...
The conditioning regimen was designed to be reduced-toxicity myeloablative and did not include serotherapy. Graft-versus-host disease (GVHD) prophylaxis initially comprised a calcineurin inhibitor ...
Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.
Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as ...